BACKGROUND: The rare patient diagnosed with pure ductal carcinoma-in-situ (DCIS) develops distant breast cancer metastases (DM). We sought to identify clinical and pathologic predictors of DM. METHODS: The clinical and pathologic characteristics of patients with DM after a diagnosis of pure DCIS from 1996 to 2009 were analyzed. RESULTS: Twenty five patients with DM after an initial diagnosis of DCIS were identified; 3 were treated at our institution and 22 were originally treated elsewhere. The rate of DM was 0.14% among 2,123 patients originally treated at our institution. Among all patients with DM, 73.7% had DCIS with necrosis, and 62% had DCIS that did not express estrogen receptor. Twenty-four percent of patients with DM were African American, compared to 11.5% of the total study population. The median time from DCIS to DM was 4.5 years. Sixteen patients (66%) had a preceding or simultaneous invasive locoregional recurrence (LRR); nine (34%) did not. At last follow-up, 14 patients (56%) had died of disease; median time to death was 2.4 years. No dominant variables could be identified in patients who developed DM with or without a LRR. CONCLUSIONS: DM after a diagnosis of pure DCIS is rare. Although most patients with DM have a preceding invasive LRR, some present with subsequent DM alone. Further study is required to identify clinical and pathologic predictors of this more rapid disease progression.
BACKGROUND: The rare patient diagnosed with pure ductal carcinoma-in-situ (DCIS) develops distant breast cancer metastases (DM). We sought to identify clinical and pathologic predictors of DM. METHODS: The clinical and pathologic characteristics of patients with DM after a diagnosis of pure DCIS from 1996 to 2009 were analyzed. RESULTS: Twenty five patients with DM after an initial diagnosis of DCIS were identified; 3 were treated at our institution and 22 were originally treated elsewhere. The rate of DM was 0.14% among 2,123 patients originally treated at our institution. Among all patients with DM, 73.7% had DCIS with necrosis, and 62% had DCIS that did not express estrogen receptor. Twenty-four percent of patients with DM were African American, compared to 11.5% of the total study population. The median time from DCIS to DM was 4.5 years. Sixteen patients (66%) had a preceding or simultaneous invasive locoregional recurrence (LRR); nine (34%) did not. At last follow-up, 14 patients (56%) had died of disease; median time to death was 2.4 years. No dominant variables could be identified in patients who developed DM with or without a LRR. CONCLUSIONS:DM after a diagnosis of pure DCIS is rare. Although most patients with DM have a preceding invasive LRR, some present with subsequent DM alone. Further study is required to identify clinical and pathologic predictors of this more rapid disease progression.
Authors: Marc D Ryser; Laura H Hendrix; Mathias Worni; Yiling Liu; Terry Hyslop; E Shelley Hwang Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Carolina Rodriguez-Tirado; Nupura Kale; Maria J Carlini; Nitisha Shrivastava; Alcina A Rodrigues; Bassem D Khalil; Jose Javier Bravo-Cordero; Yan Hong; Melissa Alexander; Jiayi Ji; Fariba Behbod; Maria Soledad Sosa Journal: Cancer Res Date: 2022-06-15 Impact factor: 13.312
Authors: Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling Journal: Nat Rev Cancer Date: 2022-10-19 Impact factor: 69.800
Authors: Gaiane M Rauch; Henry M Kuerer; Marion E Scoggins; Patricia S Fox; Ana P Benveniste; Young Mi Park; Sara A Lari; Brian P Hobbs; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang Journal: Breast Cancer Res Treat Date: 2013-06-18 Impact factor: 4.872
Authors: Gaiane M Rauch; Brian P Hobbs; Henry M Kuerer; Marion E Scoggins; Ana P Benveniste; Young Mi Park; Abigail S Caudle; Patricia S Fox; Benjamin D Smith; Beatriz E Adrada; Savitri Krishnamurthy; Wei T Yang Journal: Ann Surg Oncol Date: 2015-09-28 Impact factor: 5.344
Authors: Hung D Tran; Krishna Luitel; Michael Kim; Kun Zhang; Gregory D Longmore; David D Tran Journal: Cancer Res Date: 2014-08-27 Impact factor: 12.701
Authors: Niamh Buckley; David Boyle; Darragh McArt; Gareth Irwin; D Paul Harkin; Tong Lioe; Stephen McQuaid; Jacqueline A James; Perry Maxwell; Peter Hamilton; Paul B Mullan; Manuel Salto-Tellez Journal: Oncotarget Date: 2015-12-22
Authors: Jun Ho Lee; Sung Yong Kim; Jeong Eon Lee; Eun Yoon Cho; Yoon-La Choi; Joon Young Choi; Sun Wook Han; Seok Won Kim; Won Ho Kil; Seok Jin Nam Journal: J Breast Cancer Date: 2014-03-28 Impact factor: 3.588